UI Hospitals and Clinics
Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Participants in this study are at least 70 years of age and have acute myeloid leukemia (AML). Also, the patient has decided against the use of standard intensive treatment for the AML. The purpose of the first part of this study is to confirm the safety and tolerability of giving sapacitabine in alternating cycles with decitabine. The purpose of the second part of this study is to learn which, among several drug options, is more likely to keep the patient's cancer in check as long as possible. This research study will involve approximately 470 subjects at approximately 50 locations. Participation will continue until the disease gets worse or the study closes.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.